Using Recombinant Activated Factor VIIa to Treat Bleeding in Major Abdominal Surgery
Author Information
Author(s): Christian von Heymann, Sven Jonas, Claudia Spies, Klaus-Dieter Wernecke, Sabine Ziemer, Detlev Janssen, Jürgen Koscielny
Primary Institution: Charité-University Medicine Berlin
Hypothesis
What is the role of recombinant activated factor VII (rFVIIa) in abdominal, vascular, and urological surgery?
Conclusion
The study found that rFVIIa can significantly reduce bleeding and improve survival rates in patients who respond to the treatment.
Supporting Evidence
- 73.2% of patients experienced a reduction or cessation of bleeding after rFVIIa administration.
- Survival probability increased to 66% among patients who responded to rFVIIa.
- Only 10% of patients who did not respond to rFVIIa survived.
Takeaway
This study shows that a medicine called rFVIIa can help stop bleeding in patients who have had major surgery, and it can also help them live longer if it works.
Methodology
Meta-analysis of case series and placebo-controlled studies on the treatment or prophylaxis of bleeding with rFVIIa.
Potential Biases
Case reports may be subject to publication bias, affecting the perceived efficacy of rFVIIa.
Limitations
The study is limited by the lack of randomized controlled trials and potential publication bias in case reports.
Participant Demographics
The study included patients undergoing major abdominal surgeries without pre-existing coagulation disorders.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI 51.0% to 95.4%
Statistical Significance
p=0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website